Literature DB >> 27697063

Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.

David Hsu1, Gad A Marshall2.   

Abstract

The field of Alzheimer disease (AD) prevention has been a culmination of basic science, clinical, and translational research. In the past three years since the new 2011 AD diagnostic guidelines, large-scale collaborative efforts have embarked on new clinical trials with the hope of someday preventing AD. This review will shed light on the historical and scientific contexts in which these trials were based on, as well as discuss potential challenges these trials may face in the coming years. Primary preventive measures, such as lifestyle, multidomain, medication, and supplemental interventions, will be analyzed. Secondary prevention as represented by disease-modifying interventions, such as antiamyloid therapy and pioglitazone, will also be reviewed. Finally, hypotheses on future directions for AD prevention trials will be proposed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Alzheimer disease; anxiety; hypertension.; neuropsychological; pathophysiology

Mesh：

Year:  2017        PMID： 27697063      PMCID： PMC5329133          DOI： 10.2174/1567205013666160930112125

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN： 1567-2050            Impact factor:   3.498


  76 in total

Review 1.  Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.

Authors:  D J Selkoe
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  Leisure activities and the risk of dementia in the elderly.

Authors:  Joe Verghese; Richard B Lipton; Mindy J Katz; Charles B Hall; Carol A Derby; Gail Kuslansky; Anne F Ambrose; Martin Sliwinski; Herman Buschke
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

3.  Influence of social network on occurrence of dementia: a community-based longitudinal study.

Authors:  L Fratiglioni; H X Wang; K Ericsson; M Maytan; B Winblad
Journal:  Lancet       Date:  2000-04-15       Impact factor: 79.321

Review 4.  Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association.

Authors:  P B Gorelick; R L Sacco; D B Smith; M Alberts; L Mustone-Alexander; D Rader; J L Ross; E Raps; M N Ozer; L M Brass; M E Malone; S Goldberg; J Booss; D F Hanley; J F Toole; N L Greengold; D C Rhew
Journal:  JAMA       Date:  1999 Mar 24-31       Impact factor: 56.272

5.  Effects of cognitive training interventions with older adults: a randomized controlled trial.

Authors:  Karlene Ball; Daniel B Berch; Karin F Helmers; Jared B Jobe; Mary D Leveck; Michael Marsiske; John N Morris; George W Rebok; David M Smith; Sharon L Tennstedt; Frederick W Unverzagt; Sherry L Willis
Journal:  JAMA       Date:  2002-11-13       Impact factor: 56.272

6.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Authors:  James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

7.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Authors:  Sally A Shumaker; Claudine Legault; Stephen R Rapp; Leon Thal; Robert B Wallace; Judith K Ockene; Susan L Hendrix; Beverly N Jones; Annlouise R Assaf; Rebecca D Jackson; Jane Morley Kotchen; Sylvia Wassertheil-Smoller; Jean Wactawski-Wende
Journal:  JAMA       Date:  2003-05-28       Impact factor: 56.272

Review 8.  An active and socially integrated lifestyle in late life might protect against dementia.

Authors:  Laura Fratiglioni; Stephanie Paillard-Borg; Bengt Winblad
Journal:  Lancet Neurol       Date:  2004-06       Impact factor: 44.182

9.  Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.

Authors:  Sally A Shumaker; Claudine Legault; Lewis Kuller; Stephen R Rapp; Leon Thal; Dorothy S Lane; Howard Fillit; Marcia L Stefanick; Susan L Hendrix; Cora E Lewis; Kamal Masaki; Laura H Coker
Journal:  JAMA       Date:  2004-06-23       Impact factor: 56.272

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321
View more
  22 in total

Review 1.  Small-molecule PET Tracers for Imaging Proteinopathies.

Authors:  Chester A Mathis; Brian J Lopresti; Milos D Ikonomovic; William E Klunk
Journal:  Semin Nucl Med       Date:  2017-07-13       Impact factor: 4.446

Review 2.  Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease.

Authors:  Elizabeth C Mormino; Kathryn V Papp
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 3.  Genetic testing for neurodegenerative diseases: Ethical and health communication challenges.

Authors:  J Scott Roberts; Anne K Patterson; Wendy R Uhlmann
Journal:  Neurobiol Dis       Date:  2020-04-14       Impact factor: 5.996

4.  Machine learning for comprehensive prediction of high risk for Alzheimer's disease based on chromatic pupilloperimetry.

Authors:  Yael Lustig-Barzelay; Ifat Sher; Inbal Sharvit-Ginon; Yael Feldman; Michael Mrejen; Shada Dallasheh; Abigail Livny; Michal Schnaider Beeri; Aron Weller; Ramit Ravona-Springer; Ygal Rotenstreich
Journal:  Sci Rep       Date:  2022-06-15       Impact factor: 4.996

5.  Editorial: Current and Emerging Therapeutics in AD.

Authors:  Marwan Sabbagh; Boris Decourt
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

6.  α1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid β1-42-stimulated murine astrocytes.

Authors:  Taraneh Ebrahimi; Marcus Rust; Sarah Nele Kaiser; Alexander Slowik; Cordian Beyer; Andreas Rembert Koczulla; Jörg B Schulz; Pardes Habib; Jan Philipp Bach
Journal:  J Neuroinflammation       Date:  2018-09-27       Impact factor: 8.322

7.  Using a birth cohort to study brain health and preclinical dementia: recruitment and participation rates in Insight 46.

Authors:  Sarah-Naomi James; Christopher A Lane; Thomas D Parker; Kirsty Lu; Jessica D Collins; Heidi Murray-Smith; Michelle Byford; Andrew Wong; Ashvini Keshavan; Sarah Buchanan; Sarah E Keuss; Diana Kuh; Nick C Fox; Jonathan M Schott; Marcus Richards
Journal:  BMC Res Notes       Date:  2018-12-13

Review 8.  Preclinical progression of neurodegenerative diseases.

Authors:  Masahisa Katsuno; Kentaro Sahashi; Yohei Iguchi; Atsushi Hashizume
Journal:  Nagoya J Med Sci       Date:  2018-08       Impact factor: 1.131

9.  Insulin receptor sensitization restores neocortical excitation/inhibition balance in a mouse model of autism.

Authors:  Fu-Sun Lo; Reha S Erzurumlu
Journal:  Mol Autism       Date:  2018-02-22       Impact factor: 7.509

10.  Antia, a Natural Antioxidant Product, Attenuates Cognitive Dysfunction in Streptozotocin-Induced Mouse Model of Sporadic Alzheimer's Disease by Targeting the Amyloidogenic, Inflammatory, Autophagy, and Oxidative Stress Pathways.

Authors:  Nesrine S El Sayed; Mamdooh H Ghoneum
Journal:  Oxid Med Cell Longev       Date:  2020-06-17       Impact factor: 6.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.